Log in
Enquire now
LoQus23

LoQus23

LoQus23 is a small molecule drugs developer for Huntington's disease founded in 2019 by David Reynolds.

OverviewStructured DataIssuesContributors

Contents

loqus23.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Health technology
Health technology
Biotechnology
Biotechnology
Location
United Kingdom
United Kingdom
Cambridge, Cambridgeshire
Cambridge, Cambridgeshire
0
CEO
‌
David Reynolds
Founder
‌
David Reynolds
‌
Caroline Benn
Pitchbook URL
pitchbook.com/profiles...277398-91
Number of Employees (Ranges)
1 – 10
Full Address
Building 522 Babraham Research Campus Cambridge CB22 3AT, UK0
Investors
Dementia Discovery Fund
Dementia Discovery Fund
Novartis Venture Fund
Novartis Venture Fund
Forbion Capital Partners
Forbion Capital Partners
Founded Date
2019
Total Funding Amount (USD)
52,300,000
Latest Funding Round Date
October 2, 2024
Latest Funding Type
Series A
Series A
Country
United Kingdom
United Kingdom
0

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
43,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like LoQus23

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.